Medtronic will manufacture the IN.PACT Admiral drug-coated balloon (DCB) for the treatment of peripheral artery disease (PAD) at a new facility in Galway, Ireland.
According to a press release, this decision has been made to exploit the existing high-tech capability and expertise in drug-device combination products at the site, which has been involved in Medtronics coronary business. Approximately 100 highly skilled professionals from other areas of Medtronic, specialising in quality and manufacturing engineering, supply chain and production management, will be located at the facility.
The announcement was made in Galway with a site-visit from Richard Bruton, and Michael Lohan, manager of Medical Technologies Division, IDA Ireland.
Richard Bruton says, “Manufacturing is a key sector which we have targeted as part of the Action Plan for Jobs, and over the past four years we have seen the sector perform well after years of neglect. The investment in Galway today by Medtronic is a great example of the type of manufacturing projects we are trying to develop in Ireland – highly-skilled jobs, manufacturing innovative products, for sale in global markets. I wish Tony and the team every success with this project.”
Martin Shanahan, CEO, IDA Ireland says, “This announcement once again showcases Ireland’s position as a global hub for medical technologies, with this country employing the highest number of medical technologies personnel per capita in Europe. We have worked over a period of time with Medtronic to bring this capability and project to fruition in Ireland. The decision by Ireland and the IDA several decades ago to attract major medical and other technology companies to Ireland via state investment and support infrastructure continues to enable Ireland to reap the benefits.”
Tony Semedo, senior vice president and president of the Aortic & Peripheral Vascular business at Medtronic, states that the investment showed Ireland’s importance to Medtronic’s overall growth strategy.
“Our Galway operations and staff have very specific expertise in this area, which is the platform for this announcement. Once fully operational, this facility will be the only DCB manufacturing area of its kind in Medtronic worldwide.”
The facility will have 20,000 square feet of space with 8,000 square feet dedicated to manufacturing and will cost approximately €13 million. It has been specifically designed to meet the needs of the manufacturing process associated with the IN.PACT Admiral drug-coated balloon (DCB).
